Should I Buy TERN? TERN 2026 Analysis

Should You Buy Terns Pharmaceuticals Inc (TERN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

39.450

1 Day change

0.25%

52 Week Range

48.260

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Terns Pharmaceuticals Inc (TERN) is not a strong buy for a beginner, long-term investor at this moment. While the company has promising analyst ratings and a positive drug development pipeline, insider selling, lack of recent news catalysts, weak financial performance, and neutral trading sentiment suggest waiting for better entry points.

Technical Analysis

The technical indicators show a bullish trend with MACD above 0, RSI in the neutral zone at 55.821, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). Key support is at 34.447, and resistance is at 39.084. However, the stock's short-term trend suggests a slight probability of decline (-0.29% in the next week, -3.72% in the next month).

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The options data indicates bearish sentiment, with a high put-call volume ratio of 2.29, suggesting more put activity compared to calls.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have consistently raised price targets, with the latest target as high as $60, citing the promising potential of TERN-701 as a best-in-class treatment for chronic myeloid leukemia. The drug's strong safety and efficacy profile, along with a large market opportunity, are key drivers of optimism.

Neutral/Negative Catalysts

Insider selling has increased significantly (1103.41% over the last month), which may indicate a lack of confidence from company insiders. Additionally, hedge funds are neutral, and there are no recent news catalysts to drive momentum. The financial performance remains weak, with negative net income and declining EPS.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$24.64M (improved by 12.26% YoY), and a drop in EPS to -0.27 (-3.57% YoY). The company is still in its clinical-stage development phase with no revenue generation.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly optimistic, with multiple firms raising price targets to $54-$60 and maintaining Outperform or Buy ratings. The consensus is based on the strong potential of TERN-701 in the chronic myeloid leukemia market, with a $4.8B opportunity in the frontline setting and additional revenue potential in second-line and beyond.

11 Analyst Rating

Wall Street analysts forecast TERN stock price to rise

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 39.350

Low

Averages

54.22

High

Current: 39.350

Low

Averages

54.22

High

Leerink

Outperform

initiated

$58

AI Analysis

2026-02-09

Reason

Leerink

Price Target

$58

AI Analysis

2026-02-09

initiated

Outperform

Reason

Leerink initiated coverage of Terns Pharmaceuticals with an Outperform rating and $58 price target. Terns is a clinical-stage biotechnology company developing TERN-701, a next-generation allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia. Early phase 1 TERN-701 CARDINAL data suggest a best-in-class profile, with materially higher molecular response rates and a clean safety profile that affords a wider therapeutic window enabling deeper and more durable target suppression, the firm notes. The frontline CML setting is the primary driver of value for TERN-701, which Leerink sees as a $4.8B opportunity, $32/share in its model. At Terns's current $4B market valuation, conviction in TERN-701's ability to meaningfully penetrate the frontline setting is paramount to the long thesis. The firm forecasts an additional $1.4B of second-line-and-beyond peak revenues or $18/share in its model.

Citizens

Outperform

maintain

$35 -> $57

2025-12-11

Reason

Citizens

Price Target

$35 -> $57

2025-12-11

maintain

Outperform

Reason

Citizens raised the firm's price target on Terns Pharmaceuticals to $57 from $35 and keeps an Outperform rating on the shares. Terns' interim Phase 1 CARDINAL ASH update highlighted the best-in-class profile of TERN-701, the analyst tells investors in a research note. Key additional data points were the high deep molecular response rate, setting it up well in 1L, and the strong activity post asciminib and ponatinib, which is very positive in 2L, Citizens says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TERN

Unlock Now

TERN Should I Buy

TERN Should I Buy

Should You Buy Terns Pharmaceuticals Inc (TERN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch